Form 8-K - Current report:
SEC Accession No. 0001193125-26-205011
Filing Date
2026-05-05
Accepted
2026-05-05 07:06:38
Documents
11
Period of Report
2026-05-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rgen-20260505.htm   iXBRL 8-K 50738
2 EX-99.1 rgen-ex99_1.htm EX-99.1 715517
3 GRAPHIC img109360391_0.jpg GRAPHIC 5520
  Complete submission text file 0001193125-26-205011.txt   915642

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT rgen-20260505.xsd EX-101.SCH 27846
14 EXTRACTED XBRL INSTANCE DOCUMENT rgen-20260505_htm.xml XML 4509
Mailing Address 41 SEYON STREET BUILDING 1, SUITE 100 WALTHAM MA 02453
Business Address 41 SEYON STREET BUILDING 1, SUITE 100 WALTHAM MA 02453 7814499560
REPLIGEN CORP (Filer) CIK: 0000730272 (see all company filings)

EIN.: 042729386 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-14656 | Film No.: 26940402
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)